Pharmacological treatments for core symptoms of Autism Spectrum Disorder (ASD) are still lacking. The clinical heterogeneity observed in this population (e.g., differences in cognitive functioning or in autism symptom severity) should be taken into account when a new drug is tested. Stratifying this population according to its neurobiological substrate could significantly improve our knowledge regarding the most appropriate pharmacological treatment for individual needs. In this review, we discuss the possible genetic and biological pathways, including the Glutamatergic, GABAergic, and mTOR systems, involved in the pathophysiology of autism, as well as the mechanisms that may be targeted by new drug interventions. Finally, we describe the current progress from the preclinical and clinical studies on some potential therapeutic options for ASD core symptoms.

Mazzone, L., Giovagnoli, G., Siracusano, M., Postorino, V., & Curatolo, P. (2017). Drug Treatments for Core Symptoms of Autism Spectrum Disorder: Unmet Needs and Future Directions. JOURNAL OF PEDIATRIC NEUROLOGY, 15(3), 134-141 [10.1055/s-0037-1602823].

Drug Treatments for Core Symptoms of Autism Spectrum Disorder: Unmet Needs and Future Directions

Mazzone, L
;
Siracusano, M;Curatolo, P
2017

Abstract

Pharmacological treatments for core symptoms of Autism Spectrum Disorder (ASD) are still lacking. The clinical heterogeneity observed in this population (e.g., differences in cognitive functioning or in autism symptom severity) should be taken into account when a new drug is tested. Stratifying this population according to its neurobiological substrate could significantly improve our knowledge regarding the most appropriate pharmacological treatment for individual needs. In this review, we discuss the possible genetic and biological pathways, including the Glutamatergic, GABAergic, and mTOR systems, involved in the pathophysiology of autism, as well as the mechanisms that may be targeted by new drug interventions. Finally, we describe the current progress from the preclinical and clinical studies on some potential therapeutic options for ASD core symptoms.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/39 - Neuropsichiatria Infantile
English
pharmacological treatments; autism spectrum disorder; genetic pathways; mTOR; bumetanide; memantine; arbaclofen; oxytocin; folinic acid
Mazzone, L., Giovagnoli, G., Siracusano, M., Postorino, V., & Curatolo, P. (2017). Drug Treatments for Core Symptoms of Autism Spectrum Disorder: Unmet Needs and Future Directions. JOURNAL OF PEDIATRIC NEUROLOGY, 15(3), 134-141 [10.1055/s-0037-1602823].
Mazzone, L; Giovagnoli, G; Siracusano, M; Postorino, V; Curatolo, P
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Drug-Treatments-for-Core-Symptoms-of-Autism-Spectrum-Disorder-Unmet-Needs-and-Future-Directions.pdf

accesso aperto

Licenza: Copyright dell'editore
Dimensione 300.65 kB
Formato Adobe PDF
300.65 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/194028
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact